Description
This research blend combines CJC-1295 and Ipamorelin (5mg + 5mg per vial) to study the growth-hormone axis from two complementary angles within a single preparation.
CJC-1295 is investigated for its capacity to provide sustained GHRH-type signaling, while Ipamorelin contributes selective growth-hormone release through the ghrelin receptor. Together they offer a synergistic model for laboratory work on GH-axis regulation.
Intended for laboratory and in-vitro experimental use exclusively. Not for human consumption.


Reviews
There are no reviews yet.